Compare Salesforce Inc (CRM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs 10X Genomics Inc — how do they compare? Salesforce Inc trades at $229.13 (market cap $187.48B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Salesforce Inc is far larger — about 18.6× 10X Genomics Inc's market cap, and Salesforce Inc pays a 0.77% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and 10X Genomics Inc for 91 Days on average.
| CRM | TXG | |
|---|---|---|
Market Cap | $187.48B | $10.07B |
Volume | 6,155,822 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $266.23 | $97.74 |
52-Week Low | $150.12 | $11.48 |
Typical Hold Time | 89 Days | 91 Days |
Enterprise Value | $217.82B | $9.59B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $227.80, up 1.44% with strong fundamentals including 77.28% gross margins and consistent earnings beats. The stock shows bearish technical signals but maintains robust revenue growth trajectory from $37.9B in 2025 to projected $43.9B in 2026. Recent AI-driven innovations like Agentforce and Data 360 show promising monetization potential with $2.9B ARR growth.
Despite technical headwinds, Salesforce presents compelling value with 76.5% analyst buy ratings and $271.91 price target representing 19% upside. Key risks include AI competition pressure and software sector volatility, but strong cash flow generation and market leadership support long-term growth prospects.
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
